Table 2.
Characteristics of 189 patients with clear cell RCC treated with ICB therapies.
| All (n = 189) | |
|---|---|
| Age at treatment (years)—median (range) | 60 (34, 89) |
| Sex | |
| Male | 142 (75%) |
| Histology subtype | |
| Clear cell RCC | 189 (100%) |
| IMDC risk score at starting ICB therapy | |
| Good | 54 (29%) |
| Intermediate | 102 (54%) |
| Poor | 24 (13%) |
| Missing | 9 (5%) |
| ICB therapy type | |
| Single-agent IO | 75 (40%) |
| IO + IO combination | 38 (20%) |
| IO + VEGF combination | 71 (38%) |
| IO + other treatment combination | 5 (3%) |
| Line of ICB therapy | |
| First line | 97 (51%) |
| ≥Second line | 92 (49%) |
| PBRM1 mutation type | |
| LOF | 61 (32%) |
| Non-LOF | 27 (14%) |
ICB immune-checkpoint blockade, IMDC International Metastatic Renal Cell Carcinoma Database Consortium, LOF loss of function.